AEGEAN: A phase 3 trial of neoadjuvant durvalumab+chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
B Haager, John V. Heymach(The University of Texas MD Anderson Cancer Center), David H. Harpole(Duke University Hospital), Tetsuya Mitsudomi(Kindai University), Janis M. Taube(Sidney Kimmel Cancer Center), Gabriella Gálffy(County Hospital), Maximilian J. Hochmair, Thomas Winder(Landeskrankenhaus Feldkirch), Р. А. Зуков(Krasnoyarsk State Medical University), Gabriel Garbaos, Jie He(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Hiroaki Kuroda(Aichi Cancer Center), Jing You(Tianjin Medical University Cancer Institute and Hospital), KY Lee(Taipei Medical University-Shuang Ho Hospital), Lorenzo Antonuzzo(University of Florence), M Aperghis(AstraZeneca (United Kingdom)), Gary J. Doherty(AstraZeneca (United Kingdom)), Helen Mann(AstraZeneca (United Kingdom)), Tamer M. Fouad(AstraZeneca (Brazil)), Martin Reck(German Center for Lung Research), Christian Schumann
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie
August 1, 2023
Cited by 10
Abstract
Related Papers
No related papers found
Powered by citation graph analysis